Navigation Links
New Multi-Modal Contrast Agents, A Boon For Medical Imaging

Medical imaging techniques like ultrasound and computed tomography (CT), magnetic resonance imaging and molecular imaging can all be made better by the newly developed multi-modal contrast agent – Researchers // at the University of Illinois at Urbana-Champaign says.

Use of these new agents may, in turn, significantly improve the diagnosis and treatment of cancer, according to Kenneth Watkin, a professor in the department of speech and hearing science and the Beckman Institute for Advanced Science and Technology.

Watkin's findings, the result of work with former graduate student Michael McDonald, who is now completing a postdoctoral fellowship at Stanford University, were published recently in the journal Academic Radiology.

‘The goal of this work for me was to be able to create advanced methods for the treatment of disease, specifically cancer, that reduce the toxic effects that we see with our current treatments,’ Watkin said. ‘And to do that, I had to develop really, really, really small carriers.

‘I got into this field -- which is really nanomedicine -- because my area of interest is imaging and head and neck cancer,’ he said. ‘And as I would do imaging studies, I would see the true devastation of chemotherapy and radiation therapy to individuals from a psychosocial and a body point of view. So I got to thinking, 'How could we treat head and neck cancers differently -- using fewer chemotoxins?'

The tiny carriers Watkin and McDonald are proposing would, in effect, zero in on tumors in much the same way that smart bombs take aim at strategic targets.

Watkin's transport system of choice are nanoparticles of gadolinium oxide.

The best way to visualize these nanoparticles, Watkin said, is to think of them as ‘exceptionally tiny pouches.’ Or better yet, ‘like the trailer on a semi-truck. The deliverer is the targeting body and the trailer is the little shell that contains the material.’


'"/>




Page: 1 2 3 4

Related medicine news :

1. Lowering Contrast Material Injection in Aged Patients is Cost-effective and can Offset Risks
2. In Elderly Patients Lowering Contrast Material Injection Will Reduce Costs
3. Using Contrast Enhanced Sonography Improves Diagnosis of Liver and Spleen Injuries
4. MRI Contrast Agent Linked to Complication in Renal Patients
5. CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Meditation Works Medically
8. Sleep Disorders Could Indicate Other Medical Problems
9. Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging
10. Hypnosis Found To Reduce Stress In Children During Medical Procedures
11. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...ies, those called up to risk their lives in the se...d even ill-treated. Apparently the US is no except... their grievances during a hearing of the Presiden...l at Washington on Saturday. Speaking from exper...
...euticals Incorporated, a global biotechnology comp...rial on new hepatitis C drug, telaprevir. The drug...t has been shown. The planned interim results of ...nnounced at Barcelona on Saturday at the 42nd Annu...
...ted pessimism hangs thickly over Britain’s junior ...th since UK’s young doctors took the street in pro...te of most of them having dished out thousands of ... that would make them eligible for NHS employment....
...ts at Bonn University have created a software syst...l implants significantly. //With the aid of the so... exactly those signals, which are expected and can...two dozens of patients in Germany and the U.S. hav...
Other Medicine News:Health News:Military Healthcare Lacks Compassion, Say US Soldiers 2Health News:New Hepatitis C Drug Shows Promise 2Health News:UK’s Junior Doctors Losing Hop 2Health News:Software System to Improve the Function of Retinal Implants 2Health News:Software System to Improve the Function of Retinal Implants 3
(Date:9/3/2008)...l Vascular Disease Awareness Month, CHARLOTTESVIL...euticals,LLC, a clinical-stage drug-development co...of unmet medical needs, announced today that it ha...l trial of its lead drug,candidate trans sodium cr...,on the clinicaltrials.gov Website, is investigati...
(Date:9/3/2008)...taq(R) (dronedarone) decreased the risk of,stroke ...al flutter already adequately treated...pt. 3 /- The results of a,p... were presented today at,the clinical trial update...gress 2008, in Munich, Germany. Previous results f...
(Date:9/3/2008)...s Strong Evidence Pycnogenol(R) Lowers Joint, Pain...Following Cessation of... -- According to the Center for,Disease Control (C...itis,is on the rise. A new study published in the...Pycnogenol(R), bark extract from the French mariti...
(Date:9/2/2008)...re-FirstCall/ -- Forest Laboratories, Inc.,(NYSE: ...nced results from,two global Phase III studies of ...ticholinergic for the treatment of patients with c...th the ACCLAIM/COPD I&II,(AClidinium CLinical Tria...ere COPD Patients) studies, once-daily aclidinium ...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6AmerisourceBergen Technology Group Opens New Facility in Buffalo Grove Illinois 1239 1AmerisourceBergen Technology Group Opens New Facility in Buffalo Grove Illinois 1239 2AmerisourceBergen Technology Group Opens New Facility in Buffalo Grove Illinois 1239 3Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Direct 1236 1Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Direct 1236 2Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Direct 1236 3Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Direct 1236 4Microtek Medical Receives Early Termination of Hart Scott Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab 1233 1Microtek Medical Receives Early Termination of Hart Scott Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab 1233 2Microtek Medical Receives Early Termination of Hart Scott Rodino Act Waiting Period for Its Proposed Acquisition by Ecolab 1233 3Spiritual Healer Psychic Medium Reaches International Status 21 1230 1Spiritual Healer Psychic Medium Reaches International Status 21 1230 2
... Nasalfent shows clinically meaningful pain relief..., READING, England, 7 June 2007 - Archimedes Pharm...eutical company, today,presented new clinical data...ive fentanyl citrate nasal spray aimed at providin...reakthrough cancer,pain. Data were presented at th...
...Orexigen(TM) is evaluating zonisamide SR as a nove..., SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ ...utical company focused on the,treatment of central... obesity, today announced results from a Phase I t... novel, proprietary,sustained-release (SR) formul...
Other Medicine Technology:Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
The Vitek is a completely automated instrument that offers Rapid results (with an average of 2 - 6 hour same day turnaround), random or batch processing and a quality control module. It is used for b
IDS Rapid One, a microbial identification system.
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in
The SkanWasher 300 is an automatic 96-well microplate washer designed to give reliable, reproducible results, with no cross-contamination between wells, and no carryover from plate to plate. The wash
Medicine Products: